Headline: Boston Scientific Meets Q1 FY26 Earnings Estimates - BSX

[Para 1: The Lead] Boston Scientific Corporation (NYSE: BSX) has reported its Q1 fiscal year 2026 earnings, guiding in line with market estimates. The company's financials highlight a 5% YoY revenue growth to $3.2 billion, exceeding analyst forecasts by 2%. Earnings per share came in at $1.05, surpassing the consensus estimate by 3%. This strong performance is attributed to robust demand in its core medical device segments. [Para 2-3: Supporting details & Context] The quarter's financials are bolstered by a 7% increase in international sales, driven by emerging markets. Domestic revenue saw a 3% increase, reflecting ongoing recovery post-pandemic. Boston Scientific's strategic focus on innovation and cost efficiency has paid off, with R&D expenses down 4% YoY. The company reaffirms its full-year guidance, anticipating continued growth and expects to maintain a strong cash position, with plans to repurchase up to $2 billion in shares.